George M. Jenkins
Known title: DirectorCIK: 0001271081
George M. Jenkins's purchase track record
How the stock did after each of George M. Jenkins's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since December 18, 2024
Stock higher 6 months later
100%
3 months: 75%
Median 6-month return
+50.2%
3 months: +29.1%
Beat the S&P 500
75%
median +38.7% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/30/2026 | PVLA | $50K | +39.9% | +26.4% | +21.1% |
| 2/27/2026 | PVLA | $500K | -12.3% | +11.1% | +12.1% |
| 4/9/2025 | PVLA | $101K | +18.4% | +243.3% | +23.8% |
| 12/18/2024 | PVLA | $52K | +134.2% | +74.0% | +1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PVLA | ▼ Sell | Open Market | 954 | $143K | 9/15/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 263 | $40K | 9/15/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 560 | $85K | 9/15/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 5,632 | $853K | 9/14/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 6,160 | $937K | 9/14/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 1,560 | $239K | 9/14/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 6,520 | $982K | 9/11/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 4,577 | $694K | 9/11/2026 | View on chart |
| PVLA | ▼ Sell | Open Market | 1,274 | $195K | 9/11/2026 | View on chart |
| PVLA | ▲ Buy | Open Market | 445 | $50K | 3/30/2026 | View on chart |
| PVLA | ▲ Buy | Open Market | 4,000 | $500K | 2/27/2026 | View on chart |
| PVLA | ▲ Buy | Open Market | 2,500 | $50K | 4/9/2025 | View on chart |
| PVLA | ▲ Buy | Open Market | 2,490 | $50K | 4/9/2025 | View on chart |
| PVLA | ▲ Buy | Open Market | 4,000 | $52K | 12/18/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Palvella Therapeutics Shares New Data at Dermatology Conference
Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.
Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.